Inflammatory protein profile during systemic high dose interleukin-2 administration

Leonardo Rossi, Brian M. Martin, Glen L. Hortin, Richard L. White, Mareva Foster, Ramy Moharram, David Stroncek, Ena Wang, Francesco M. Marincola, Monica C. Panelli

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Systemic interleukin-2 (IL-2) administration induces an assortment of downstream effects whose biological and therapeutic significance remains unexplored mostly because of the methodological inability to globally address their complexity. Protein array analysis of sera from patients with renal cell carcinoma obtained prior and during high-dose IL-2 therapy had previously revealed extensive alterations in expression of the soluble factors analyzed, whose discovery was limited by the number of capture antibodies selected for protein detection. Here, we expanded the analysis to SELDI-TOF-MS and quantitative protein analysis (nephelometry). All cytokines/chemokines detected by protein arrays were below the SELDI detection limit, while novel IL-2-specific changes in expression of acute-phase reactants and high-density lipoprotein metabolites could be identified. Serum amyloid protein A (SAA) and C-reactive protein expression were consistently up-regulated after four doses of IL-2, while other proteins were down-regulated. These findings were confirmed by SELDI immunoaffinity capture and nephelometry. Immunoaffinity capture revealed different, otherwise undetectable, isoforms of SAA. A linear correlation between peak area by SELDI and protein concentration by nephelometry was observed. Overall distinct yet complementary information was obtained using different platforms, which may better illustrate complex phenomena such as the systemic response to biological response modifiers.

Original languageEnglish
Pages (from-to)709-720
Number of pages12
JournalProteomics
Volume6
Issue number2
DOIs
Publication statusPublished - Jan 2006
Externally publishedYes

Fingerprint

Nephelometry and Turbidimetry
Interleukin-2
Protein Array Analysis
Proteins
Amyloidogenic Proteins
Serum Amyloid A Protein
Acute-Phase Proteins
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Immunologic Factors
HDL Lipoproteins
Protein C
Chemokines
Renal Cell Carcinoma
C-Reactive Protein
Limit of Detection
Blood Proteins
Protein Isoforms
Cytokines
Metabolites
Antibodies

Keywords

  • Acute phase reactant
  • Interleukin-2
  • Nephelometry
  • Renal cancer
  • SELDI-TOF MS

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Rossi, L., Martin, B. M., Hortin, G. L., White, R. L., Foster, M., Moharram, R., ... Panelli, M. C. (2006). Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics, 6(2), 709-720. https://doi.org/10.1002/pmic.200500004

Inflammatory protein profile during systemic high dose interleukin-2 administration. / Rossi, Leonardo; Martin, Brian M.; Hortin, Glen L.; White, Richard L.; Foster, Mareva; Moharram, Ramy; Stroncek, David; Wang, Ena; Marincola, Francesco M.; Panelli, Monica C.

In: Proteomics, Vol. 6, No. 2, 01.2006, p. 709-720.

Research output: Contribution to journalArticle

Rossi, L, Martin, BM, Hortin, GL, White, RL, Foster, M, Moharram, R, Stroncek, D, Wang, E, Marincola, FM & Panelli, MC 2006, 'Inflammatory protein profile during systemic high dose interleukin-2 administration', Proteomics, vol. 6, no. 2, pp. 709-720. https://doi.org/10.1002/pmic.200500004
Rossi L, Martin BM, Hortin GL, White RL, Foster M, Moharram R et al. Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics. 2006 Jan;6(2):709-720. https://doi.org/10.1002/pmic.200500004
Rossi, Leonardo ; Martin, Brian M. ; Hortin, Glen L. ; White, Richard L. ; Foster, Mareva ; Moharram, Ramy ; Stroncek, David ; Wang, Ena ; Marincola, Francesco M. ; Panelli, Monica C. / Inflammatory protein profile during systemic high dose interleukin-2 administration. In: Proteomics. 2006 ; Vol. 6, No. 2. pp. 709-720.
@article{485167219bb04f1b85b088e32656df03,
title = "Inflammatory protein profile during systemic high dose interleukin-2 administration",
abstract = "Systemic interleukin-2 (IL-2) administration induces an assortment of downstream effects whose biological and therapeutic significance remains unexplored mostly because of the methodological inability to globally address their complexity. Protein array analysis of sera from patients with renal cell carcinoma obtained prior and during high-dose IL-2 therapy had previously revealed extensive alterations in expression of the soluble factors analyzed, whose discovery was limited by the number of capture antibodies selected for protein detection. Here, we expanded the analysis to SELDI-TOF-MS and quantitative protein analysis (nephelometry). All cytokines/chemokines detected by protein arrays were below the SELDI detection limit, while novel IL-2-specific changes in expression of acute-phase reactants and high-density lipoprotein metabolites could be identified. Serum amyloid protein A (SAA) and C-reactive protein expression were consistently up-regulated after four doses of IL-2, while other proteins were down-regulated. These findings were confirmed by SELDI immunoaffinity capture and nephelometry. Immunoaffinity capture revealed different, otherwise undetectable, isoforms of SAA. A linear correlation between peak area by SELDI and protein concentration by nephelometry was observed. Overall distinct yet complementary information was obtained using different platforms, which may better illustrate complex phenomena such as the systemic response to biological response modifiers.",
keywords = "Acute phase reactant, Interleukin-2, Nephelometry, Renal cancer, SELDI-TOF MS",
author = "Leonardo Rossi and Martin, {Brian M.} and Hortin, {Glen L.} and White, {Richard L.} and Mareva Foster and Ramy Moharram and David Stroncek and Ena Wang and Marincola, {Francesco M.} and Panelli, {Monica C.}",
year = "2006",
month = "1",
doi = "10.1002/pmic.200500004",
language = "English",
volume = "6",
pages = "709--720",
journal = "Proteomics",
issn = "1615-9853",
publisher = "Wiley-VCH Verlag",
number = "2",

}

TY - JOUR

T1 - Inflammatory protein profile during systemic high dose interleukin-2 administration

AU - Rossi, Leonardo

AU - Martin, Brian M.

AU - Hortin, Glen L.

AU - White, Richard L.

AU - Foster, Mareva

AU - Moharram, Ramy

AU - Stroncek, David

AU - Wang, Ena

AU - Marincola, Francesco M.

AU - Panelli, Monica C.

PY - 2006/1

Y1 - 2006/1

N2 - Systemic interleukin-2 (IL-2) administration induces an assortment of downstream effects whose biological and therapeutic significance remains unexplored mostly because of the methodological inability to globally address their complexity. Protein array analysis of sera from patients with renal cell carcinoma obtained prior and during high-dose IL-2 therapy had previously revealed extensive alterations in expression of the soluble factors analyzed, whose discovery was limited by the number of capture antibodies selected for protein detection. Here, we expanded the analysis to SELDI-TOF-MS and quantitative protein analysis (nephelometry). All cytokines/chemokines detected by protein arrays were below the SELDI detection limit, while novel IL-2-specific changes in expression of acute-phase reactants and high-density lipoprotein metabolites could be identified. Serum amyloid protein A (SAA) and C-reactive protein expression were consistently up-regulated after four doses of IL-2, while other proteins were down-regulated. These findings were confirmed by SELDI immunoaffinity capture and nephelometry. Immunoaffinity capture revealed different, otherwise undetectable, isoforms of SAA. A linear correlation between peak area by SELDI and protein concentration by nephelometry was observed. Overall distinct yet complementary information was obtained using different platforms, which may better illustrate complex phenomena such as the systemic response to biological response modifiers.

AB - Systemic interleukin-2 (IL-2) administration induces an assortment of downstream effects whose biological and therapeutic significance remains unexplored mostly because of the methodological inability to globally address their complexity. Protein array analysis of sera from patients with renal cell carcinoma obtained prior and during high-dose IL-2 therapy had previously revealed extensive alterations in expression of the soluble factors analyzed, whose discovery was limited by the number of capture antibodies selected for protein detection. Here, we expanded the analysis to SELDI-TOF-MS and quantitative protein analysis (nephelometry). All cytokines/chemokines detected by protein arrays were below the SELDI detection limit, while novel IL-2-specific changes in expression of acute-phase reactants and high-density lipoprotein metabolites could be identified. Serum amyloid protein A (SAA) and C-reactive protein expression were consistently up-regulated after four doses of IL-2, while other proteins were down-regulated. These findings were confirmed by SELDI immunoaffinity capture and nephelometry. Immunoaffinity capture revealed different, otherwise undetectable, isoforms of SAA. A linear correlation between peak area by SELDI and protein concentration by nephelometry was observed. Overall distinct yet complementary information was obtained using different platforms, which may better illustrate complex phenomena such as the systemic response to biological response modifiers.

KW - Acute phase reactant

KW - Interleukin-2

KW - Nephelometry

KW - Renal cancer

KW - SELDI-TOF MS

UR - http://www.scopus.com/inward/record.url?scp=32144452617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32144452617&partnerID=8YFLogxK

U2 - 10.1002/pmic.200500004

DO - 10.1002/pmic.200500004

M3 - Article

VL - 6

SP - 709

EP - 720

JO - Proteomics

JF - Proteomics

SN - 1615-9853

IS - 2

ER -